Pipeline: Our current focus is on dermal delivery of analgesics with an emphasis on controlled drugs (e.g. fentanyl) for pain-relief as well as to develop bioactive wound care products to enhance healing and to minimize pain and scarring.
Market Potential: The market potential is significant and there is a clear unmet need for patient-centric dermal solutions that our versatile technology platform is uniquely placed to deliver.
Our pipeline reflects this:
Market and Opportunity for Lidocaine Patches: Lidocaine patches are a large and growing market-opportunity with over $1.4B in annual sales Learn more.
Market and Opportunity for Fentanyl Patches: The global opioids market revenue is projected at 42.2 billion USD by 2021. In 2016, Fentanyl transdermal patches alone represented close to 17% of the US Transdermal Patch market Learn more.
Market & Opportunity for EGF Patches and Bioactive Wound Dressings: The bioactive wound care market for use of biologics such as Growth Factors (e.g. EGF) in wound healing is projected to be ~1-2 billion USD with a huge potential for growth at CAGR of 14% Learn more.
Competitive edge: Our technology provides a clear competitive edge in terms of efficacy and efficiency (at least 30 times less drug used to get the same effect) with minimum residual drug in the used patch to ensure ease of disposal. The unique protective properties of silica matrix allow the production of bioactive patches. (e.g. containing growth factors like EGF) for the treatment of deep skin wounds such as burns.
Results: We have obtained very positive preclinical data which has demonstrated the superior efficiency of our patch. In partnership with a European patch manufacturer, we are currently prototyping our first nanocomposite patch (Lidocaine) to test in humans. Given our preclinical data and the benign nature of the excipients, we anticipate that the early clinical trials will confirm the efficiency of our system and demonstrate its compatibility with extended duration of application on the skin. Once the safety and efficacy of the system has been demonstrated for lidocaine, it will also clear the clinical path for the use of our technology for delivery of other pain relief products, including opioids.
What we are looking for: We are looking for investors who would want to participate in our exciting journey to further develop this ground-breaking technology and take it through early stage clinical trials.
Exit Strategy: Our goal is to license the technology for specific therapeutic applications to patch or wound dressing manufacturers or pharmaceutical companies active in the dermal space.